ConcertAI today announced the acquisition of CancerLinQ, previously a subsidiary of the American Society of Clinical Oncology (ASCO). In conjunction with the acquisition, ASCO will maintain a multi-year cooperation agreement with CancerLinQ. Building on CancerLinQ’s mission when launched by ASCO in 2013, this new venture will enhance and expand CancerLinQ’s use of real-world data, analytics, next-generation AI, and other technologies to improve cancer care and speed clinical research.
December 11, 2023
November 17, 2023
President Biden announced on Nov. 17, 2023, the appointment of W. Kimryn Rathmell, MD, PhD, Chair of Medicine at Vanderbilt University Medical Center, and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics, as his choice for director of the National Cancer Institute (NCI).
November 16, 2023
Congress passed a two-tiered continuing resolution (CR) on November 15, 2023, extending FY 2023 federal funding levels until February 2, 2024, for all Department of Health and Human Services agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI). The president is expected to sign the bill.
November 6, 2023
The addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor domvanalimab to the programmed cell death protein 1 (PD-1) inhibitor zimberelimab and chemotherapy may improve outcomes for patients with advanced gastroesophageal cancer. These results will be presented during the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
November 6, 2023
A first-in-class antibody-drug conjugate called CMG901 targeting claudin 18.2 (also referred to as CLDN18.2) may be a potential new treatment option for patients with claudin 18.2-positive gastric or gastroesophageal junction cancer. These results will be presented during the November 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
October 24, 2023
Ensuring every patient has access to high-quality, patient-centered, coordinated cancer care is the goal of ASCO Certified, a new program from the Association for Clinical Oncology (ASCO).
October 23, 2023
A new interventional study found that participation in virtual mind-body fitness classes reduced hospitalizations, length of hospital stays, and urgent care visits by half. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium taking place October 28-29 in Boston.
October 23, 2023
Patients with head and neck cancer undergoing radiation treatment may experience side effects that can lead to declines in physical functioning and increase healthcare utilization. According to a new study, yoga may help alleviate these negative side effects, especially when family caregivers also participate, and decrease the use of feeding tube placements and emergency department visits. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, taking place October 28-29 in Boston.
October 23, 2023
A new study showed that a text-based e-triage program in combination with routine laboratory testing could safely “fast track” patients to treatment with immune checkpoint inhibitors, eliminating the need for an in-person assessment with their doctor, and save patients 66 minutes in total care time and 30 minutes in total wait time per visit to the healthcare center. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, taking place October 27-28 in Boston.
October 17, 2023
The American Society of Clinical Oncology and Association for Clinical Oncology (ASCO) are urging members of the Senate Committee on Health, Education, Labor, and Pensions to approve the nomination of Monica M. Bertagnolli, MD, FACS, FASCO, as the next Director of the National Institutes of Health (NIH) during its October 18, 2023, hearing.
October 2, 2023
ALEXANDRIA, Va. –– The American Society of Clinical Oncology (ASCO) has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials. The statement, published today in Lancet Oncology, emphasizes the urgent need to understand the long-term impacts of cancer therapies on ovarian function.
September 28, 2023
ASCO has released a statement on the how an impending government shutdown will impact cancer research and scientific progress.
September 20, 2023
Three studies exploring interventions to improve the quality of life for patients with cancer will be highlighted in the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. The interventions included yoga-based supportive care, a virtual mind-body fitness program, and a text-based e-triage system.
September 14, 2023
The House Energy and Commerce Subcommittee on Health will hold a hearing today on several bills aimed at addressing the ongoing U.S. drug shortage crisis. Many of the bills contain provisions the Association for Clinical Oncology supports as effective means to mitigate and prevent drug shortages and promote a more resilient supply chain in the future.
September 5, 2023
The American Society of Clinical Oncology (ASCO) will join the President’s Cancer Panel on Sept. 7 to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve the president’s Cancer Moonshot goal of “ending cancer as we know it.”
Pages |